Volume 5 Supplement 8
Towards human central nervous system in vitromodels for preclinical research: strategies for 3D neural cell culture
© Simão et al; licensee BioMed Central Ltd. 2011
Published: 22 November 2011
The development of new drugs for human Central Nervous System (CNS) diseases has traditionally relied on 2D in vitro cell models and genetically engineered animal models. However, those models often diverge considerably from that of human phenotype (anatomical, developmental and biochemical differences)  contributing to a high attrition rate - only 8% of CNS drugs entering clinical trials end up being approved . Human 3D in vitro models are useful complementary tools towards more accurate evaluation of drug candidates in pre-clinical stages, as they present an intermediate degree of complexity in terms of cell-cell and cell-matrix interactions, between the traditional 2D monolayer culture conditions and the complex brain and can be a better starting point for the analysis of the in vivo context. Aiming at developing novel 3D in vitro models of the CNS, this work focus on the implementation of long-term cultures of human midbrain-derived neural stem cells (hmNSC) for the scalable supply of neural-subtype cells, with a focus on the dopaminergic lineage, following a systematic technological approach based on stirred culture systems.
Materials and methods
Cell culture: hmNSC were isolated as previously reported  and routinely propagated in static conditions, on poly-L-ornithine-fibronectin (PLOF) coated plates, in serum-free propagation medium, containing basic fibroblast growth factor and epidermal growth factor . hmNSC were cultured in stirred systems in Cultispher S microcarriers (Percell Biolytica) without coating and coated with PLOF) or as neurospheres for 7 to 21 days, with media changes every 3-4 days. All experiments were performed in 125 mL shake flasks (20 mL working volume), with orbital shaking at 100 rpm. Cultures were maintained at 37°C, in 3% O2. Double stain viability test: aggregates were collected from stirred cultures, incubated with fluorescein diacetate (10 μg/mL) and propidium iodide (1 μg/mL) and observed on a fluorescence microscope (Leica DMI6000). Aggregate size was measured in pictures taken from each culture sample using Image J software (NIH), as previously reported . Dissociation: For microcarrier cultures, Cultispher S was allowed to settle, washed with PBS and digested with Trypsin 0.05%-EDTA (Gibco). Cells were collected by centrifugation and counted by trypan blue exclusion dye. Free cells were counted using the same aliquot. Aggregates were dissociated with Accutase (Sigma).
The inoculum concentration of 2x105 cell/mL was as efficient as 4x105 cell/mL in promoting cell aggregation (Figure 1A) whereas it allowed for lower mean diameters along culture time (362±32 μm at day 14) as compared to the higher inoculum concentration for which significantly higher mean diameter and also a wider range of aggregate sizes were observed (475±103 μm at day 14) (Figure 1B). Moreover, the lower inoculum concentration avoided the formation of necrotic centres, which were detected in cultures with an inoculum concentration of 4x105 cell/mL (Figure 1C).Taken together the data presented indicates that 2x105 cell/mL is the most favourable inoculum concentration for culture of hmNSC as aggregates in stirred culture systems.
In this study the feasibility of culturing hmNSC as 3D structures in stirred culture systems was evaluated. Cell aggregates (neurosphere) culture, using an inoculum concentration of 2x105 cell/mL was selected as the best strategy, due to the higher cell viabilities and tightly control of aggregate diameter attained. The implemented 3D culture system will be applied in the optimization of differentiation of hmNSC into dopaminergic neurons, astrocytes and oligodendrocytes.
The authors acknowledge the FP7 EU project BrainCAV (HEALTH-HS_2008_222992) and the FCT project PTDC/EBB-BIO/112786/2009 for financial support.
- Gagliardi C, Bunnell BA: Large animal models of neurological disorders for gene therapy. ILAR J. 2009, 50: 128-143.PubMed CentralView ArticlePubMedGoogle Scholar
- Miller G: Is pharma running out of brainy ideas?. Science. 2010, 329: 502-504. 10.1126/science.329.5991.502.View ArticlePubMedGoogle Scholar
- Milosevic J, Schwarz SC, Ogunlade V, Meyer AK, Storch A, Schwarz J: Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol Neurodegener. 2009, 4: 25-10.1186/1750-1326-4-25.PubMed CentralView ArticlePubMedGoogle Scholar
- Serra M, Brito C, Costa E, Sousa MFQ, Alves PM: Integrating human stem cell expansion and neuronal differentiation in bioreactors. BMC Biotechnology. 2009, 8: 92-Google Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.